Nexentis Technologies owns MitoCareX Bio, leveraging its MITOLINE platform to accelerate small-molecule discovery in collaboration with Boltz.
3 reports, 3 independent
Updated Wed 00:00
No new developments lately
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Nexentis Technologies owns MitoCareX Bio, leveraging its MITOLINE platform to accelerate small-molecule discovery in collaboration with Boltz.
How it developed
Newest first. Tap a step to see who reported it.MitoCareX deployed infrastructure on Google Cloud Platform.1 source
Nexentis utilizes MitoCareX Bio's platform to advance small-molecule discovery.1 source